Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its development pipeline. Those milestones for CYB003, the company’s deuterated psilocybin analog program, include the completion of phase 2 topline safety and … Continue reading InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones